OSLO, Norway--(BUSINESS WIRE)--The Annual General meeting in Nordic Nanovector AS will be held on Wednesday May 14, 2014 at 10:00 CET in the Company’s offices at Kjelsåsveien 168 B, 4th floor, Oslo.
Below please find the agenda, attendance form and the Annual report for 2013.
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat Non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
This information was brought to you by Cision http://news.cision.com